Atriva Therapeutics GmbH, corporate

Atriva Therapeutics GmbH,

20.09.2022 - 10:16:24

EQS-News: Atriva Therapeutics announces Topline Results from the Proof of Concept / Phase 2a RESPIRE study in patients hospitalized with COVID-19

and follow us on LinkedIn and Twitter.

?

Contact:Atriva Therapeutics GmbH Dr. Rainer Lichtenberger, CEO phone: +49 69 9999 162 10 mobile: +49 151 7443 3175lichtenberger@atriva-therapeutics.com Media and Investor Relations:MC Services AG Eva Bauer / Raimund Gabriel phone: +49 89 210 228 80atriva-therapeutics@mc-services.eu

?

References

[1] ?Atriva Therapeutics GmbH. 2022. A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19 (RESPIRE).

[2] ?https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis.

[3] ?Pleschka S et al. Nat Cell Biol 2001 Feb 3:301-5.

[4] ?Pleschka S. 2008. Biol Chem. 389, 1273?1282.

[5] ?Haasbach E et al. Antiviral Res 2017 Jun 142:178-4.

[6] ?Laure M et al. Antiviral Res 2020 Jun 178:104806.

[7] ?Schreiber A et al. 2022. Cell Mol Life Sci. 79(1):65.

[8] ?Planz O Antiviral Res 2013 Jun 98(3):457-68.

[9] ?Pinto R et al. Antiviral Res 2011 Oct 92(1):45-56.

[10] ?Ragab D et al. 2020. Front Immunol. 11, 1446 (2020).

20.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

1445945??20.09.2022?CET/CEST

@ dgap.de